Peloton Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 64

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.35B

Peloton Therapeutics General Information

Description

Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. It is focused on targeting HIF-2a, a transcription factor which was thought to be intractable using a small molecule. The company's drug candidate, PT2977, has shown clinical proof of concept in patients with advanced or metastatic clear cell renal cell carcinoma.

Contact Information

Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 2330 Inwood Road
  • Suite 226
  • Dallas, TX 75235
  • United States
+1 (972)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 2330 Inwood Road
  • Suite 226
  • Dallas, TX 75235
  • United States
+1 (972)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Peloton Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 20-Sep-2019 $2.35B Completed Clinical Trials - Phase 2
8. IPO 26-Apr-2019 Cancelled Clinical Trials - Phase 2
7. Later Stage VC (Series E) 20-Feb-2019 Completed Generating Revenue
6. Later Stage VC (Series D) 14-Mar-2017 Completed Clinical Trials - Phase 2
5. Grant 05-Aug-2016 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 05-Nov-2014 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 18-Dec-2013 Completed Startup
2. Grant $11M $18M Completed Startup
1. Early Stage VC (Series A) 27-Jul-2011 $18M $18M Completed Startup
To view Peloton Therapeutics’s complete valuation and funding history, request access »

Peloton Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 10,080,000 $0.000100 $0.1 $1.25 $1.25 1x $1.25 7.68%
Series A 17,100,000 $0.000100 $0.08 $1 $1 1x $1 13.03%
To view Peloton Therapeutics’s complete cap table history, request access »

Peloton Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights
Drug Discovery
Dallas, TX
64 As of 2019

Vienna, VA
 

Englewood, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Peloton Therapeutics Competitors (92)

One of Peloton Therapeutics’s 92 competitors is CEL-SCI, a Corporation company based in Vienna, VA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CEL-SCI Corporation Vienna, VA
Ampio Pharmaceuticals Corporation Englewood, CO
AB Science Formerly Accelerator/Incubator backed Paris, France
Hansa Biopharma Corporation Lund, Sweden
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 92 competitors. Get the full list »

Peloton Therapeutics Patents

Peloton Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025184010-A1 N-biaryl sulfonamides as modulators of the hippo pathway Pending 01-Mar-2024
EP-4387610-A1 Tricyclic sultams and sulfamides as antitumor agents Pending 12-Oct-2021
EP-4387610-A4 Tricyclic sultams and sulfamides as antitumor agents Pending 12-Oct-2021
US-20240294548-A1 Tricyclic sultams and sulfamides as antitumor agents Pending 12-Oct-2021
WO-2023064058-A1 Tricyclic sultams and sulfamides as antitumor agents Inactive 12-Oct-2021 C07D513/04
To view Peloton Therapeutics’s complete patent history, request access »

Peloton Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Peloton Therapeutics FAQs

  • When was Peloton Therapeutics founded?

    Peloton Therapeutics was founded in 2011.

  • Where is Peloton Therapeutics headquartered?

    Peloton Therapeutics is headquartered in Dallas, TX.

  • What is the size of Peloton Therapeutics?

    Peloton Therapeutics has 64 total employees.

  • What industry is Peloton Therapeutics in?

    Peloton Therapeutics’s primary industry is Drug Discovery.

  • Is Peloton Therapeutics a private or public company?

    Peloton Therapeutics is a Private company.

  • What is the current valuation of Peloton Therapeutics?

    The current valuation of Peloton Therapeutics is .

  • What is Peloton Therapeutics’s current revenue?

    The current revenue for Peloton Therapeutics is .

  • How much funding has Peloton Therapeutics raised over time?

    Peloton Therapeutics has raised $287M.

  • Who are Peloton Therapeutics’s competitors?

    CEL-SCI, Ampio Pharmaceuticals, AB Science, Hansa Biopharma, and Crinetics Pharmaceuticals are some of the 92 competitors of Peloton Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process